[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiomyopathy-hypertrophic-obstructive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiomyopathy-hypertrophic-obstructive":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100650913","bhb-1893-versus-metoprolol-for-symptomatic-obstructive-hypertrophic-cardiomyopathy-100650913",false,"NCT07755904","BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy","A Phase 3, Multi-region, Multi-center, Randomized, Double-blind, Active-Comparator-Controlled Trial to Evaluate the Efficacy and Safety of BHB-1893 Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy","LIONHEART-HCM","Key Inclusion Criteria:\n\n* Diagnosed with oHCM per the protocol specified criteria\n* NYHA Class II or III at screening visits\n* KCCQ-CSS that meets the protocol specified criteria at screening visits\n* Adequate acoustic windows for echocardiography\n\nKey Exclusion Criteria:\n\n* Medical indication for either β-blocker or calcium-channel blocker therapy, other than oHCM, prohibiting drug discontinuation\n* History of intolerance or medical contraindication to β-blocker therapy\n* Resting systolic blood pressure (SBP) of \\>160 millimeters of mercury (mmHg) at screening visits\n* Resting heart rate of \\>100 beats per minute (bpm) at screening visits\n* Significant valvular heart disease, defined as:\n\n  * Moderate to severe valvular aortic stenosis or fixed subaortic obstruction;\n  * Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator's judgment)\n\nOther protocol-defined criteria apply.","ALL","18 Years","85 Years",{"count":21,"type":22},210,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.",[28],"Cardiomyopathy, Hypertrophic Obstructive",[30,31],"oHCM","BHB-1893","NOT_YET_RECRUITING","2026-08-05",{"date":35,"type":36},"2026-08-10","ACTUAL",{"date":38,"type":22},"2026-10",{"date":40,"type":22},"2028-11",{"name":42,"class":43},"Braveheart Bio, Inc.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100648092","impact-cmh-impact-of-mitral-valve-and-subvalvular-abnormalities-in-obstructive-hypertrophic-cardiomyopathy-treated-with-mavacamten-100648092","NCT07716826","IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten","IMPACT-CMH","Inclusion Criteria:\n\n* Inclusion Criteria :\n* Age ≥18 years\n* Patients who are informed and consent to participate\n* CMH with significant obstruction (left intraventricular gradient at rest or during Valsalva maneuver ≥ 50 mmHg) and symptomatic (NYHA class 2 or 3)\n* Patients who have started treatment with Mavacamten\n\nExclusion Criteria:\n\n* Patients who refuse to participate in this register",{"count":52,"type":22},150,"OBSERVATIONAL","The objective of this observational study is to evaluate the association between the presence of mitral valvular and\u002For subvalvular anatomical abnormalities prior to initiation of mavacamten and the hemodynamic response at 6 months in patients with obstructive HCM treated with mavacamten. The secondary objective is to determine the impact of different types of anatomical abnormalities of the mitral valve and subvalvular structures on the hemodynamic and clinical response to mavacamten.",[28],[28,57,58,59],"mavacamten","mitral valve","subvalvular structures","2026-07-16",{"date":62,"type":36},"2026-07-21",{"date":64,"type":22},"2026-09",{"date":66,"type":22},"2026-12",{"name":68,"class":69},"French Cardiology Society","OTHER"]